Drug-Delivery Technology Market Report 2026

The drug-delivery technology market size has grown rapidly in recent years. It will grow from $54.24 billion in 2025 to $60.27 billion in 2026 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to growth in chronic diseases, advancements in pharmaceutical formulations, demand for improved patient compliance, expansion of injectable therapies, innovation in medical devices.

The drug-delivery technology market size is expected to see rapid growth in the next few years. It will grow to $91.41 billion in 2030 at a compound annual growth rate (CAGR) of 11%. The growth in the forecast period can be attributed to rise of personalized medicine, increasing biologics and biosimilars, demand for long acting drug delivery, technological advances in implantables, growing home care treatment adoption. Major trends in the forecast period include targeted drug delivery systems, controlled and sustained release formulations, patient centric drug delivery devices, minimally invasive delivery technologies, advanced implantable drug systems.

The rising prevalence of chronic diseases is expected to drive the growth of the drug-delivery technology market. Chronic diseases are long-term medical conditions that typically develop gradually and require continuous management. The increase in chronic diseases is largely linked to sedentary lifestyles, which reduce physical activity and contribute to obesity and related health complications. Drug-delivery technology supports the management of chronic diseases by enabling targeted delivery, controlled release, better bioavailability, and fewer side effects, ultimately improving treatment effectiveness, patient compliance, and overall disease control. For example, in July 2024, the Australian Burden of Disease Study 2023 from the Australian Institute of Health and Welfare (AIHW) reported that chronic conditions accounted for 91% of non-fatal burden (years lived with disability) and 78% of fatal burden (years of life lost) in 2023. Therefore, the increasing prevalence of chronic diseases is contributing to the growth of the drug-delivery technology market.

Leading companies in the drug-delivery technology market are focusing on the development of innovative products such as prefilled injection devices to improve patient convenience, enhance dosing accuracy, and ensure safer drug administration. A prefilled injection device is a medical device that comes preloaded with a specific dose of medication, eliminating the need for manual drug filling before use. For example, in February 2023, Phillips-Medisize LLC, a US-based medical equipment manufacturer, launched a new disposable pen injector designed for high-volume manufacturing. The injector features a compact and flexible design with customizable dosing and push-button colors, supporting multiple therapies such as diabetes, fertility, growth hormones, obesity, and osteoporosis. This device aims to help pharmaceutical companies speed up market entry by offering a cost-effective, ready-to-use solution, while also reducing commercialization costs and risks.

In January 2025, Molex, a U.S.-based provider of electronic interconnect, packaging, and connectivity solutions (through its Phillips Medisize subsidiary, a CDMO for drug delivery), acquired Vectura Group Ltd. for an undisclosed amount. Through this acquisition, Molex/Phillips Medisize aims to strengthen its drug-delivery technology portfolio by incorporating Vectura’s established inhalation formulation and device-development expertise, allowing for more comprehensive respiratory and combination therapy solutions. Vectura Group Ltd. is a UK-based company specializing in inhalation drug-device design, formulation development, and combination product manufacturing for dry powder inhalers, metered dose inhalers, nebulizers, and nasal inhalers.

Major companies operating in the drug-delivery technology market are Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc., Cipla Limited, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Chiesi Farmaceutici S.p.A., United Therapeutics Corporation, Mallinckrodt Pharmaceuticals Plc., Lupin Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Alkermes plc., Halozyme Therapeutics Inc., Sunovion Pharmaceuticals Inc., and Circassia Pharmaceuticals Plc.

North America was the largest region in the drug-delivery technology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug-delivery technology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug-delivery technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the drug delivery technology market by increasing costs of imported medical devices, specialized polymers, and precision manufacturing equipment. These cost pressures have affected injectable, implantable, and transdermal delivery segments more significantly due to their reliance on global component supply chains. Regions such as north america and europe have experienced moderate price increases driven by dependence on international manufacturing hubs. At the same time, tariffs have encouraged local production of drug delivery devices and materials. This has supported domestic manufacturing capabilities and improved supply chain resilience. Over time, regional investments are helping stabilize costs and sustain innovation.

The drug-delivery technology market research report is one of a series of new reports that provides drug-delivery technology market statistics, including drug-delivery technology industry global market size, regional shares, competitors with a drug-delivery technology market share, detailed drug-delivery technology market segments, market trends and opportunities, and any further data you may need to thrive in the drug-delivery technology industry. This drug-delivery technology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Drug-delivery technology refers to advanced systems and devices designed to deliver pharmaceutical compounds to specific areas of the body in a controlled and efficient manner. These technologies aim to improve the therapeutic effects of medications, minimize side effects, and enhance patient compliance through various delivery methods, including oral, injectable, transdermal, and implantable systems.

The primary types of drug-delivery technology include oral, injectable, topical, ocular, nasal, pulmonary, transmucosal, and implantable methods. Oral drug delivery involves taking medication via the mouth, typically in the form of tablets or capsules. This method offers convenience and improved effectiveness by utilizing enhanced solubility and absorption technologies. It is used in treating a range of conditions, including cardiovascular diseases, oncology, urology, diabetes, central nervous system (CNS) disorders, ophthalmology, and infections, and is applied in settings such as hospitals, clinics, diagnostic centers, home care, and others.

The drug-delivery technology market consists of revenues earned by entities by providing services such as custom drug formulation, controlled-release drug delivery systems, injectable drug delivery solutions, nanosystems for drug delivery, and transdermal drug delivery systems. The market value includes the value of related goods sold by the service provider or included within the service offering. The drug-delivery technology market includes sales of microneedle patches, implantable pumps, oral delivery systems, biodegradable drug delivery devices, and liposome-based drug delivery systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.